| GlaxoSmithKline AG - Havrix 1440, Injektionssuspension | | 00558 | | 02 | | Havrix 1440 | | Injektionssuspension | | J07BC02 | | Hepatitis A, Inactivated, Whole Virus | | 03.09.1993 | | |
| | Composition | | Vaccinum adsorbatum: hepatitis-A-virus inactivatus (HM175) 1440 U. corresp. proteina max. 0.4 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.5 mg, aminoacida cum phenylalaninum 166 µg, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, kalii chloridum, polysorbatum 20, aqua ad iniectabile, ad suspensionem pro 1 ml corresp. natrium max. 3.6 mg et kalium max. 0.5 mg, residui: neomycini sulfas. | | Packungsbestandteile | | Injection suspension | | | | | | | | Active Agent | Dose | additional_information |
|---|
| | 1440 U/ml correspond Protein 0.4 µg/ml | Vaccinum adsorbatum |
| | BAG: Active Agent | Dose |
|---|
| | 1440 U |
| | | | Inactive agents | Dose |
|---|
| | | | | 166 µg/ml | | Disodium Phosphate | | | Potassium Chloride | | | Potassium Dihydrogenophosphate | | | Sodium Chloride | | | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | | 31.84 | 51.05 | B | SL | No |
|
|
